Investigating how the Epstein Barr virus affects immune responses in HIV patients
Programmed splicing derangement as new EBV host cell shut-off mechanism
This study is looking at how the Epstein Barr virus can become active in people with HIV/AIDS and how that might lead to certain cancers and autoimmune diseases, with the goal of finding better ways to manage these health issues.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tulane University of Louisiana NIH-funded |
| Lab location | 1 site (New Orleans, United States) |
| Project ID | NIH-11042878 on NIH RePORTER |
What this research studies
This research focuses on understanding the Epstein Barr virus (EBV) and its role in various cancers and autoimmune diseases, particularly in individuals with HIV/AIDS. The study examines how EBV can switch from a dormant state to an active one, leading to increased viral replication and potentially contributing to the development of lymphomas and autoimmune conditions. By analyzing the interactions between EBV and host cells, the research aims to uncover mechanisms that could help in managing EBV-related complications in HIV-infected patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV/AIDS who may be at risk for EBV-related complications.
Not a fit: Patients who do not have HIV/AIDS or those without any history of EBV-related conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for preventing and treating EBV-associated cancers and autoimmune diseases in HIV patients.
How similar studies have performed: Previous research has shown promising results in understanding the interactions between EBV and host immune responses, indicating that this area of study has potential for significant advancements.
Where this research is happening
New Orleans, United States
- Tulane University of Louisiana — New Orleans, United States (Active)
Researchers
- Principal investigator: Flemington, Erik K — Tulane University of Louisiana
- Study coordinator: Flemington, Erik K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.